Log In
Print
BCIQ
Print
Print this Print this
 

Firdapse, amifampridine

Also known as: 3,4-DAP, 3,4-diaminopyridine (formerly Zenas)

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionPotassium channel blocker
Molecular Target Potassium channel
Mechanism of ActionK channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat congenital myasthenic syndromes; Treat Lambert-Eaton myasthenic syndrome (LEMS)
Regulatory Designation U.S. - Breakthrough Therapy (Treat Lambert-Eaton myasthenic syndrome (LEMS));
U.S. - Orphan Drug (Treat Lambert-Eaton myasthenic syndrome (LEMS));
U.S. - Orphan Drug (Treat congenital myasthenic syndromes);
EU - Orphan Drug (Treat Lambert-Eaton myasthenic syndrome (LEMS));
Switzerland - Orphan Drug (Treat Lambert-Eaton myasthenic syndrome (LEMS))
Partner Catalyst Pharmaceuticals Inc.; Jazz Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$63.5M

$20.0M

$36.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today